• Home
  • Post a press-release
  • Visibility packages
  • Subscribe email updates
  • Event Calendar
  • Contact

For Immediate Release | Official News Wire for the Travel Industry

Where press releases are breaking news

  • Home
  • Post a press-release
  • Visibility packages
  • Subscribe email updates
  • Event Calendar
  • Contact

Archives for January 2018

Nova publicação confirma que o método inovador de combinação de medicamentos da AZTherapies trata da resposta à neuroinflamação via neuroimunologia e acumulação de beta amiloide associada à neurodegeneração e à doença de Alzheimer.

January 31, 2018 by forimmediaterelease.net -

BOSTON, 31 de janeiro de 2018 /PRNewswire/ — A AZTherapies, Inc. é um laboratório farmacêutico de estágio clínico avançado, de capital fechado, com sede em Boston, Massachusetts, que desenvolve tratamentos revolucionários para a doença de Alzheimer (DA), acidente vascular cerebral (AVC) isquêmico e outras doenças neurológicas associadas à neuroinflamação e à neurodegeneração. O principal candidato à produto, uma combinação de tratamentos multifacetados que usam dois medicamentos criados por reengenharia, cromolina e ibuprofeno, o ALZT-OP1, está sendo avaliado em um estudo clínico da Fase 3 da doença de Alzheimer em estágio inicial, o estudo COGNITE.

O fundador e chairman e CEO da empresa, dr. David Elmaleh, disse: “A AZTherapies usa critérios de inclusão estritos, incluindo biomarcadores cerebrais e medidas de cognição e função, para aumentar a precisão do diagnóstico precoce da DA e a homogeneidade de pacientes randomizados do estudo COGNITE”.

O estudo COGNITE de Fase 3 (n=600) da AZTherapies em andamento fez a triagem de mais de 900 pacientes com mais de 300 randomizados, 128 na semana 48 e 56 na semana 72, na conclusão do estudo. (https://cognitetrial.com).

“Crescentes evidências indicam o importante papel que a neuroinflamação exerce no declínio cognitivo na doença de Alzheimer e em outros distúrbios neurodegenerativos”, disse a presidente e CMO (chief medical officer) da empresa, Karen Reeves, MD. “Tratamentos inovadores para essas doenças devastadoras precisam de uma estratégia de múltiplas ações, incluindo a modulação de células microgliais, de células do sistema imune especializadas do cérebro, para aumentar a proteção neurológica”.

Um artigo de pesquisa do laboratório do dr. Rudolph Tanzi, professor de neurologia da Escola de Medicina Joseph. P. and Rose F. Kennedy, vice-presidente de Neurologia da Universidade de Harvard, diretor da Unidade de Genética e Pesquisa do Envelhecimento do Hospital Geral de Massachusetts, publicado em 18 de janeiro de 2018 na Nature’s Scientific Reports, intitulado Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis (A cromolina reduz os níveis da proteína beta amiloide associadas à doença de Alzheimer por promover a fagocitose microglial) (Zhang, Griuc, Hudry et al.; Relatórios Científicos (2018) 8:1144; DOI:10.1038/s41598-018-19641-2), dá suporte ao fundamento científico para o uso da combinação de medicamentos da AZTherapies, para potencialmente desacelerar ou interromper a progressão da DA precoce em sua manifestação. (https://www.nature.com/articles/s41598-018-19641-2)

O artigo da Scientific Reports avaliou os efeitos da cromolina e do ibuprofeno, usados no estudo COGNITE, em um modelo de camundongo Tg2576 da DA, para tratamento dos efeitos precoces sobre a formação de placas, e em ensaios de autorização de células microgliais sobre seus efeitos na ativação da micróglia como drogas anti-inflamatórias.

O artigo conclui: “Coletivamente, nossos dados revelam efeitos robustos da cromolina, sozinha ou em combinação com o ibuprofeno, na redução dos níveis de Aβ propensos à agregação e na indução de um estado de ativação da micróglia, favorecendo a fagocitose da Aβ versus um estado pró-neuroinflamatório”.

A AZTherapies (www.aztherapies.com) é uma empresa farmacêutica de estágio clinico avançado, com sede em Boston, Massachusetts. A AZTherapies está usando métodos inovadores na descoberta, desenvolvimento e comercialização de novos tratamentos para a doença de Alzheimer e AVC isquêmico, o que pode fundamentalmente melhorar o tratamento, a qualidade de vida e o controle da doença do paciente. O principal programa da empresa, o ALZT-OP1, é uma terapia de combinação composta de dois medicamentos criados por reengenharia, com perfis bem caracterizados de segurança e com propriedade intelectual protegendo a combinação de medicamentos, a dosagem, a fórmula e propriedades do medicamento, que irão levar o medicamento ao sangue e ao cérebro. A plataforma da empresa também inclui o ALZT-OP2, um potencial tratamento medicamentoso da DA modificador da doença em desenvolvimento pré-clínico avançado, o AZHALER-D, um novo inalador descartável de dose única em fase avançada de desenvolvimento, e o ALZT-QoL, um tratamento medicamentoso neurodegenerativo, criado para melhorar a qualidade de vida de pacientes com doença de Alzheimer, usando um M1 compensatório (um agonista do receptor muscarínico) com mecanismos ligantes/receptores para melhorar a conectividade da rede cerebral. Os medicamentos da AZTherapies se baseiam em tecnologias desenvolvidas no Hospital Geral de Massachusetts, um Hospital Docente da Escola de Medicina de Harvard.

Contato:
Katie Barrett
1-617-318-3426
[email protected]

Logo – https://mma.prnewswire.com/media/594208/AZTherapies_Logo.jpg

FONTE AZTherapies, Inc.

SOURCE AZTherapies, Inc.

Related Links

http://www.aztherapies.com

Share this:

  • Twitter
  • Facebook

Filed Under: Press Release

Hormel Foods Partners with Operation Gratitude to Send 52,000 Letters to Troops

January 31, 2018 by forimmediaterelease.net -

AUSTIN, Minn., Jan. 31, 2018 /PRNewswire/ — Hormel Foods Corporation (NYSE: HRL) announced today that it has partnered with Operation Gratitude and set a goal to send 52,000 letters of thanks to active duty service members overseas.

Through its sponsorship with the Super Bowl Host Committee, Hormel Foods is using its activation space at Super Bowl LIVE presented by Verizon to have attendees write letters of appreciation to deployed troops. The thank you letters will accompany 52,000 care packages sent to active duty service members by Operation Gratitude.

Hormel Foods Partners with Operation Gratitude to Send 52,000 Letters to Troops

Hormel Foods Partners with Operation Gratitude to Send 52,000 Letters to Troops

Hormel Foods Partners with Operation Gratitude to Send 52,000 Letters to Troops

Hormel Foods Partners with Operation Gratitude to Send 52,000 Letters to Troops

Hormel Foods Partners with Operation Gratitude to Send 52,000 Letters to Troops

Hormel Foods Partners with Operation Gratitude to Send 52,000 Letters to Troops

Hormel Foods Partners with Operation Gratitude to Send 52,000 Letters to Troops

“Hormel Foods has a long tradition of supporting our military. Whether it’s providing food for our troops or career opportunities when they look to transition to civilian life, Hormel Foods is there,” said Jeff Baker, group vice president of foodservice at Hormel Foods. “We are proud and inspired to partner with Operation Gratitude, and are confident we will achieve our goal of sending 52,000 thank you letters to the troops.”

“Partnering with Hormel Foods is a great opportunity for Operation Gratitude to expand its support of our military and our mission to give every American a way of expressing their appreciation to those who serve,” said Kevin Schmiegel, chief executive officer at Operation Gratitude. “These thank you letters are some of the most treasured items in our care packages and we are excited to work with Hormel Foods to accomplish this audacious goal.”

In addition to handwritten letters, the company has tablets and kiosks for people to send electronic thank you notes, and the activation space also includes a historical 1918 photo of Hormel Foods employees during a summer event. This photo includes the company’s founder, George Hormel, and his family along with the entire company staff holding signs about each department. One sign read “Stenographic department. We write letters to our troops,” further evidence of the company’s long-standing tradition of supporting our troops with letters of thanks.

An online option is available for those who are not able to attend the activation space in person. Visit https://www.hormelfoods.com/operation-gratitude/ to complete a thank you letter form.

About Hormel Foods – Inspired People. Inspired Food.™
Hormel Foods Corporation, based in Austin, Minn., is a global branded food company with over $9 billion in annual revenues across more than 80 countries worldwide. Its brands include Skippy®, SPAM®, Hormel® Natural Choice®, Applegate®, Justin’s®, Wholly Guacamole®, Hormel® Black Label® and more than 30 other beloved brands. The company is a member of the S&P 500 Index and the S&P 500 Dividend Aristocrats, was named one of “The 100 Best Corporate Citizens” by Corporate Responsibility Magazine for the ninth year in a row, and has received numerous other awards and accolades for its corporate responsibility and community service efforts. In 2016, the company celebrated its 125th anniversary and announced its new vision for the future – Inspired People. Inspired Food.™ – focusing on its legacy of innovation. For more information, visit www.hormelfoods.com and http://csr.hormelfoods.com/.

About Operation Gratitude:
Operation Gratitude, a 501(c)(3), volunteer-based organization, annually sends 250,000+ care packages to Veterans, New Recruits, First Responders, Wounded Heroes, Caregivers, and to individually named U.S. Service Members deployed overseas and their families waiting at home. Each package is filled with food, entertainment, hygiene and hand-made items, as well as personal letters of support. Operation Gratitude’s mission is to lift the spirits and meet the evolving needs of the Military and First Responder communities, and provide volunteer opportunities for civilians anywhere in America to express their appreciation to all who serve our nation. Each package contains donated product valued between $50 and $100 and costs the organization $15 to assemble and ship. Since its inception in 2003, Operation Gratitude volunteers have shipped more than 2 Million Care Packages.

Contact: Rick Williamson
507-437-5345
[email protected]

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/hormel-foods-partners-with-operation-gratitude-to-send-52000-letters-to-troops-300591609.html

SOURCE Hormel Foods Corporation

Related Links

https://www.hormelfoods.com

Share this:

  • Twitter
  • Facebook

Filed Under: Press Release

SSLJ.com Limited Announces First Closing of its Initial Public Offering

January 31, 2018 by forimmediaterelease.net -

Company to Trade on NASDAQ Capital Market Under Ticker Symbol “SSLJ”

WUHAN, China, Jan. 31, 2018 /PRNewswire/ — SSLJ.com Limited (the “Company”), a vertically integrated O2O home decoration service and product provider in China, today announced the first closing of its initial public offering (“IPO”), selling 3,819,892 Class A ordinary shares at a price to the public of $5.00 per share for a total of $19,099,460 in gross proceeds before expenses and underwriting commissions. The Company’s Class A ordinary shares are expected to begin trading on or about Monday, February 5, 2018 on The NASDAQ Capital Market (“NASDAQ”) under the ticker symbol “SSLJ.”

The registration statement relating to the securities being sold in the IPO was declared effective by the Securities and Exchange Commission (“SEC”) on January 3, 2018. The offer and sale of the IPO securities are made only by means of a prospectus. A copy of the final prospectus may be obtained by contacting the IPO’s sole underwriter, Boustead Securities, LLC Attention: Equity Capital Markets, 6 Venture, Suite 325, Irvine, CA 92618 USA, [email protected] , or by telephone at +1 949 502 4409. Ellenoff Grossman & Schole LLP acted as counsel to the Company. Boustead Securities, LLC was represented by Ortoli Rosenstadt LLP.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About SSLJ.com Limited
SSLJ.com Limited is a pioneer in the vertically integrated O2O home decoration service and product market with one of the largest market shares in China. The Company provides customers with a convenient, full-service, one-stop solution for their homes’ interior decoration and improvement needs by offering consulting, design, construction, and furnishing services as well as modern, high-quality and high-tech products. The Company has 9 branch companies and 12 sales offices in 10 cities, which are Beijing, Shanghai, Shenzhen, Wuhan, Suzhou, Hefei, Zhengzhou, Tianjin, Chengdu, Xi’an. For more information, please visit http://www.sslj.com/.

About Boustead Securities, LLC
Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information, visit http://www.boustead1828.com/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the listing of the Company’s Class A ordinary shares on NASDAQ. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the the Company’s Class A ordinary shares will be approved for listing on NASDAQ. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

For more information, please contact:

SSLJ.com Limited Contact:
Ms. Wing Chuen Rhoda Lau, CFO
Phone: +8627-8366-8638
Email: [email protected]

Investor Contact:
Ms. Tina Xiao, President
Ascent Investor Relations LLC
Phone: +1-917-609-0333
Email: [email protected]

Boustead Securities, LLC Contact: 
Dan McClory, Managing Director, Head of China, and Head of Equity Capital Markets 
Phone: +1 (949) 502-4408 
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/ssljcom-limited-announces-first-closing-of-its-initial-public-offering-300591605.html

SOURCE SSLJ.com Limited

Share this:

  • Twitter
  • Facebook

Filed Under: Press Release

Callaway Golf Company to Broadcast Fourth Quarter and Full Year 2017 Financial Results

January 31, 2018 by forimmediaterelease.net -

CARLSBAD, Calif., Jan. 31, 2018 /PRNewswire/ — Callaway Golf Company (NYSE: ELY) announced today that it will release its fourth quarter and full year 2017 financial results on Wednesday afternoon, February 7, 2018. The Company will subsequently hold a conference call with financial analysts and investors to review the results and discuss the Company’s outlook and business at 2:00 p.m. PST that same day. The call will be broadcast live over the Internet and can be accessed at http://ir.callawaygolf.com/. To listen to the call, go to the website at least 15 minutes before the call to register and for instructions on how to access the broadcast. 

A replay of the conference call will be available approximately three hours after the conclusion of the conference call. The replay may be accessed through the Internet at http://ir.callawaygolf.com/. The replay will be available through 9:00 p.m. PST on Wednesday, March 7, 2018.

About Callaway Golf
Through an unwavering commitment to innovation, Callaway Golf Company (NYSE: ELY) creates products designed to make every golfer a better golfer. Callaway Golf Company manufactures and sells golf clubs and golf balls, and sells bags, accessories and apparel in the golf and lifestyle categories, under the Callaway Golf®, Odyssey®, OGIO® and TravisMathew® brands worldwide. For more information please visit www.callawaygolf.com, www.odysseygolf.com, www.ogio.com and www.travismathew.com.

Contact:

Patrick Burke

Investor Relations

(760) 931-1771

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/callaway-golf-company-to-broadcast-fourth-quarter-and-full-year-2017-financial-results-300591608.html

SOURCE Callaway Golf Company

Related Links

http://www.callawaygolf.com

Share this:

  • Twitter
  • Facebook

Filed Under: Press Release

Una nueva publicación confirma el innovador enfoque de combinación de fármacos de AZTherapies para combatir la respuesta de la neuroinflamación mediante neuroinmunología y la acumulación de amiloide beta asociada con la neurodegeneración y la enferm

January 31, 2018 by forimmediaterelease.net -

BOSTON, 31 de enero de 2018 /PRNewswire/ — AZTherapies, Inc. es una empresa farmacéutica de fase clínica avanzada, no cotizada en bolsa, situada en Boston, Massachusetts, que está desarrollando innovadores tratamientos para la enfermedad de Alzheimer, el accidente cerebrovascular isquémico y otras enfermedades neurológicas asociadas con neuroinflamación y neurodegeneración. El principal producto candidato, una combinación de tratamiento multifacético que usa dos fármacos rediseñados, cromolina e ibuprofeno, ALZT-OP1, se está estudiando en una prueba clínica de Fase 3 del Alzheimer en etapa inicial, la prueba COGNITE.

El doctor David Elmaleh, fundador, presidente de la junta directiva y director ejecutivo de AZTherapies, dijo: “AZTherapies usa estrictos criterios de inclusión, como biomarcadores del cerebro y medidas de cognición y función para incrementar la precisión del diagnóstico inicial de enfermedad de Alzheimer y la homogeneidad de los sujetos aleatorizados para la prueba COGNITE”. 

La prueba COGNITE de Fase 3 en marcha de AZTherapies (n=600) ha examinado a más de 900 pacientes con más de 300 aleatorizados, 128 en la semana 48, y 56 en la semana 72, en la culminación del estudio. (https://cognitetrial.com)

“El aumento de la evidencia señala el importante papel que tiene la neuroinflamación en la declinación cognitiva en el Alzheimer y en otros trastornos neurodegenerativos”, dijo Karen Reeves, MD, presidenta y directora médica. “Los tratamientos innovadores para estas enfermedades devastadoras necesitan una estrategia de acción múltiple, incluida la modulación de las células microgliales, las células inmunológicas especializadas del cerebro, para mejorar la neuroprotección”. 

Un artículo de investigación del laboratorio del doctor Rudolph Tanzi, profesor de Neurología Joseph. P. y Rose F. Kennedy, Escuela de Medicina de Harvard, vicepresidente de Neurología; director de la Unidad de Genética e Investigación del Envejecimiento, Hospital General de Massachusetts, publicado el 18 de enero de 2018 en Nature’s Scientific Reports, La cromolina reduce los niveles de la proteína amiloide β asociada con la enfermedad de Alzheimer promoviendo la fagocitosis microglial ( Zhang, Griuc, Hudry y otros; Scientific Reports (2018) 8:1144; DOI:10.1038/s41598-018-19641-2) apoya la razón científica de usar la combinación de fármacos de AZTherapies para retrasar o detener potencialmente la progresión de la enfermedad de Alzheimer en las primeras etapas de su manifestación. (https://www.nature.com/articles/s41598-018-19641-2)

El artículo de Scientific Reports evaluó los efectos de la cromolina y el ibuprofeno, usados en la prueba COGNITE, en un modelo de ratones Tg2576 de la enfermedad de Alzheimer para efectos de tratamiento inicial en la formación de placa y en análisis de célula microglial sobre sus efectos en activación de microglías como fármacos antiinflamatorios.

El artículo concluye: “Colectivamente nuestros datos revelan robustos efectos de la cromolina, sola o en combinación con el ibuprofeno, para reducir los niveles de Aβ propenso a la agregación e inducir un estado de activación microglial favoreciendo la fagocitosis Aβ versus un estado pro-neuroinflamatorio”. 

AZTherapies (www.aztherapies.com) es una avanzada empresa de desarrollo de fármacos en fase clínica de Boston, Massachusetts. AZTherapies está usando enfoques innovadores en el descubrimiento, el desarrollo y la comercialización de novedosos tratamientos de la enfermedad de Alzheimer y el accidente cerebrovascular isquémico que podrían mejorar fundamentalmente el tratamiento de los pacientes, la calidad de vida y el control de la enfermedad. El programa principal de la empresa, ALZT-OP1, es una terapia de combinación compuesta por dos fármacos rediseñados con perfiles de seguridad bien conocidos con propiedad intelectual protegiendo la combinación, dosificación y formulación de los fármacos y las propiedades que suministrarán los fármacos a la sangre y al cerebro. La plataforma de la empresa también abarca ALZT-OP2, un tratamiento de fármacos para el mal de Alzheimer con el potencial de modificar la enfermedad en un estado avanzado de desarrollo preclínico; AZHALER-D, un nuevo inhalador desechable de una sola dosis en una fase avanzada de desarrollo, y ALZT-QoL, un tratamiento neurodegenerativo de fármacos creado para mejorar la calidad de vida de pacientes de la enfermedad de Alzheimer usando un M1 compensatorio (un agonista receptor muscarínico) con mecanismos ligando/receptor para mejorar la conectividad de la red cerebral. Los fármacos de AZTherapies se basan en tecnologías desarrolladas en el Hospital General de Massachusetts, un Hospital Docente de la Escuela de Medicina de Harvard.

Contacto:
Katie Barrett 
1-617-318-3426 
[email protected]

Logo – https://mma.prnewswire.com/media/594208/AZTherapies_Logo.jpg

FUENTE AZTherapies, Inc.

SOURCE AZTherapies, Inc.

Related Links

http://www.aztherapies.com

Share this:

  • Twitter
  • Facebook

Filed Under: Press Release

  • 1
  • 2
  • 3
  • …
  • 2433
  • Next Page »

Search




Recent Articles

  • Antigua & Barbuda welcomes P&O Cruises Arvia homeporting call
  • Seychelles brings its warmth to Salon Tourissima in France
  • What’s new in The Bahamas in February 2023
  • Introducing the Masquerade Suite at The St. Regis Venice in conjunction with Venice Carnival 2023
  • Malta, in the Heart of the Mediterranean, Offers a Jam-Packed Schedule of Musical Events and Festivals in 2023 Starting with Il-Karnival ta’ Malta in February   
  • Keeping Seychelles as the top choice of holiday destination for Nordic travelers
  • Sandals Resorts delivers authentic vacations
  • Seychelles makes remarkable presence at Spain’s FITUR 2023
  • The St. Regis Venice celebrates romance
  • Luxury romantic Valentine’s Day package from Blossom Hotel Houston

Subscribe to daily email update

RSS eTN Articles

  • U.S. Travel Association creates new executive position
  • Antigua & Barbuda welcomes P&O Cruises Arvia homeporting cal …
  • 6 Tips to Make Your Promo Emails Get Opened
  • 5 Best Revision Strategies for Students: Tips from a Professional Essa …
  • Cayman Islands visitors surge beyond projections
  • ITA Airways sole shareholder rushing purchase
  • Ask for Angela: Argentina nightlife fights sexual assault
  • New Acting CEO at Air Canada Pilots Association
  • Travelers would pay more for sustainable lodging
  • Seychelles brings its warmth to Salon Tourissima in France

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • November 2016
  • October 2016
  • August 2016

Content

and Breaking Travel News Business CEO experience first free hotel Hotels in including Industry International International Travel News IT minister most New News articles only over People s said sandals The World through time to TO BE tourism Tours Transportation News Travel Travel & Tourism Organizations News Travel Destination News Travelwire News up We were WHO World World News year years

Copyright © 2023 · Metro Pro on Genesis Framework · WordPress · Log in